Non-clinical and clinical pathways for rapid vaccine development in Australia

Posted by

Agilex Biolabs

Learn about the financial and speed advantages for conducting studies in Australia with an emphasis on pathways for rapid vaccine development. Key topics include: - A snapshot into the Australian Advantage - Overviews of Agilex Biolabs and our toxicology services - Considerations in nonclinical vaccine development - Case study in nonclinical safety assessment of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2 - Clinical landscape: bridging the transition from preclinical to first-in-human - Bioanalytical considerations for vaccine trials